A nucleus-targeting fluorescence probe for rapid diagnosis of colorectal cancer DOI

Yonggan Xue,

Jimei Chi,

Bobin Ning

et al.

Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 498, P. 155132 - 155132

Published: Aug. 29, 2024

Language: Английский

Histone modification inhibitors: An emerging frontier in thyroid Cancer therapy DOI
Qi Wang,

Shu Sun,

Guojun Sun

et al.

Cellular Signalling, Journal Year: 2025, Volume and Issue: unknown, P. 111703 - 111703

Published: March 1, 2025

Language: Английский

Citations

0
Reprogramming of Thyroid Cancer Metabolism: from Mechanism to Therapeutic Strategy DOI Creative Commons

Yajuan Wan,

Guoqing Li,

Gaoyuan Cui

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: March 11, 2025

Abstract Thyroid cancer as one of the most prevalent malignancies endocrine system, has raised public concern and more research on its mechanism treatment. And metabolism-based therapies have advanced rapidly, for exclusive metabolic profiling thyroid cancer. In cells, plenty pathways are reprogrammed to accommodate tumor microenvironment. this review, we initiatively summarize recent progress in full-scale rewiring interconnection various metabolites. We also discuss efficacy prospect targeted detection well therapy. Comprehending characteristics roundly will be highly beneficial managing individual patients.

Language: Английский

Citations

0
Integrative proteogenomic characterization reveals therapeutic targets in poorly differentiated and anaplastic thyroid cancers DOI Creative Commons
Zongfu Pan,

Zhuo Tan,

Ning Xu

et al.

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: April 16, 2025

Poorly differentiated thyroid cancer (PDTC) and anaplastic (ATC) present major challenges in treatment owing to extreme aggressiveness high heterogeneity. In this study, deep-scale analyses spanning genomic, proteomic, phosphoproteomic data are performed on 348 thyroid-cancer 119 tumor-adjacent samples. TP53 (48%), TERT promoter (36.5%), BRAF (23%) most frequently mutated PDTC ATC. Ribosome biogenesis is identified as a common hallmark of ATC, RRP9 silencing dramatically inhibits tumor growth. Proteomic clustering three ATC/PDTC subtypes. Pro-I subtype characterized with aberrant insulin signaling low immune cell infiltration, Pro-II featured DNA repair signaling, while Pro-III harbors frequency mutation intensive C5AR1+ myeloid infiltration. Targeting C5AR1 synergistically improves antitumor effect PD-1 blockade against ATC cell-derived tumors. These findings provide systematic insights into biology opportunities for drug discovery, accelerating precision therapy virulent cancers.

Language: Английский

Citations

0
A nucleus-targeting fluorescence probe for rapid diagnosis of colorectal cancer DOI

Yonggan Xue,

Jimei Chi,

Bobin Ning

et al.

Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 498, P. 155132 - 155132

Published: Aug. 29, 2024

Language: Английский

Citations

1